Articles

Lilly committed to China despite IP woes

Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.

Read More

Potential Lilly drug doubles good cholesterol

Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.

Read More

Supremes to decide health reform’s fate

After a year of debate followed by a year-and-a-half of recriminations, the fate of President Obama’s health care reform law will come down to a 4-1/2-hour hearing before the U.S. Supreme Court in the spring.

Read More

Potential Effient rival shows promise in study

A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.

Read More

Lilly, Amylin agree to end diabetes partnership

Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.

Read More

Glucose monitor deal helps Roche catch up

Roche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the day.

Read More

Carmel free clinic drawing jobless professionals

Trinity Free Clinic in Carmel began in 2000 to serve a growing Hispanic immigrant population. Since the latest recession, so many people—including unemployed professionals—have found their way to the clinic that the portion of white patients has grown from one-third in 2008 to 47 percent last year.

Read More